Source: ESC

Cardiology congress

ESC 2018: At the heart of research

When delegates from around 150 countries converge on Munich for ESC Congress 2018 they will no doubt reflect on what they themselves eat. Yes, nutrition is up for debate, questioning, for example, whether weight loss therapies can also prevent heart attacks and strokes.

Results from the CAMELLIA-TIMI 61 trial of 12,000 overweight individuals with established cardiovascular disease or diabetes could tell us ‘whether becoming slimmer with weight loss therapies also makes you healthier,’ explained Professor Stephan Achenbach, Chairperson of the ESC Congress Program Committee and ESC President Elect. That trial is being presented during the congress.

portrait of stephan achenbach
Professor Stephan Achenbach, Chairperson of the ESC Congress Program Committee and ESC President Elect

Additionally, the huge PURE study, which examined what constitutes a healthy diet in over 200,000 people from more than 50 countries, will be aired. ‘The results will give us new insights on the relationship between the types of food we eat – for example fruit, vegetables, nuts, dairy products and meat – and health and disease,’ Achenbach explained. The Chair also expressed excitement about other trials to be presented, with results ‘set to have a big impact, either because they affect large population groups or involve innovative treatments.’

For example, two aspiring trials to examine for preventing first heart attacks and strokes prevention will be presented – the ARRIVE trial involved more than 12,000 individuals at moderate risk and the ASCEND trial involved over 15,000 diabetics. ‘We had assumed that taking aspirin can only be good for you, and what’s the harm?’ said Achenbach. ‘But then we discovered that, while aspirin can protect against heart attacks and stroke, it causes bleeding. So it’s not at all clear who will actually benefit from taking aspirin to prevent a first heart attack or stroke. These two trials will shed light on this issue, impacting many millions of people worldwide.’

The 2018 European Society of Cardiology (ESC) and European Society of Hypertension guidelines on hypertension are another important talking point. ‘The American guidelines (released in 2017) were very strict and lowered the definition of high blood pressure. It will be exciting to see what the Europeans say about what blood pressure qualifies as “high” and how strictly it should be treated,’ Achenbach surmised.

The MARINER trial will reveal whether potentially fatal blood clots can be prevented in acutely ill patients by continuing to administer oral anticoagulation therapy after they return home. ‘Treating patients after discharge is a completely new concept and could affect the millions of people hospitalised every year with heart attack, pneumonia, or broken bones,’ Achenbach prophesised.

Oral anticoagulation is also a focus of the COMMANDER HF trial, which will reveal whether these drugs improve survival and reduce heart attack and stroke in heart failure (HF) patients who do not have atrial fibrillation. Achenbach: ‘This is a massively large patient group that so far not been considered for oral anticoagulation unless they have atrial fibrillation and the trial could change our approach to their management.’

Devices

ESC heart logo in front of congress center in barcelona
Source: ESC

Achenbach also highlighted the MITRA.fr study, which indicates whether treating the mitral valve with a device inserted via a catheter is advantageous in HF patients. 

An entire late breaking science session is devoted to transcatheter aortic valve implantation (TAVI) and is aligned to the congress spotlight, Valvular Heart Disease. This includes the LRT Clinical Trial and GARY registry in low-risk patients, the TAVI-PM study on the durability of TAVI, and the five-year follow-up from the FRANCE-2 Registry, which will report on clinical outcomes and valve durability in high-risk patients.

Major drug trials include ATTR-ACT, which assessed the efficacy and safety of tafamidis in transthyretin amyloid cardiomyopathy, a condition that currently has few treatment options. The High-STEACS trial of more than 47,000 patients will reveal whether using high-sensitivity troponin to confirm the diagnosis in those with suspected heart attack leads to more or less deaths and repeat heart attacks after one year. ‘I’m excited by how diverse cardiology is and feel it is my responsibility to represent and balance the needs of the cardiologists, healthcare providers and researchers in every country that belongs to the ESC and also across the entire spectrum of cardiovascular disease,’ Achenbach pointed out. This ethos includes spreading news of scientific findings from ESC journals and registries, guidelines, congresses, and other educational activities. 

In our special Cardiology section in European Hospital you will also learn from medical science experts how far machines and scanning skills are shaking the very roots of your discipline. 

Enjoy the stimulation of new concepts and technological developments. Enjoy EH along with ESC 2018. Welcome!

25.08.2018

Read all latest stories

Related articles

Cardiovascular MR

Standard medical tests miss nearly two-thirds of heart attack diagnoses

Standard medical tests miss nearly two-thirds of heart attack diagnoses, reveals research presented at CMR 2018. “Unrecognised MI has a poor short-term prognosis but until now the long-term outlook…

Sodium consumption

Daily salt intake: How much is too much for our heart?

New research shows that for the vast majority of individuals, sodium consumption does not increase health risks except for those who eat more than five grams a day, the equivalent of 2.5 teaspoons of…

Hazardous hormones & the heart

How being transgender affects cardiac health

Transgender individuals may be at higher risk for myocardial infarction and death due to cardiovascular disease, according to several studies. This increased risk may be due to the hormone therapy…

Related products

Research use only (RUO)

Eppendorf - Mastercycler nexus X2

Eppendorf AG

Research use only (RUO)

SARSTEDT - Low DNA Binding Micro Tubes

SARSTEDT AG & CO.

Research use only (RUO)

Shimadzu - CLAM-2000

Shimadzu Europa GmbH